Pilot Clinical Trial of Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Overview
- Phase
- Phase 1
- Intervention
- Dapagliflozin
- Conditions
- Prostate Cancer
- Sponsor
- Washington University School of Medicine
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Proportion of patients who are able to successfully complete at least 80% of the planned dapagliflozin doses and undergo radical prostatectomy
- Status
- Recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
This is a pilot study of the tolerability and safety of neoadjuvant dapagliflozin for patients with unfavorable intermediate, high-risk, or very high-risk prostatic adenocarcinoma prior to radical prostatectomy. The primary hypothesis is that four weeks of daily dapagliflozin prior to surgery is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious in resulting in tumor shrinkage on pre-operative imaging and will result in tumor necrosis at prostatectomy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically confirmed localized prostatic adenocarcinoma. Patients with primarily neuroendocrine/small cell histology will be excluded.
- •Patients with prostatic adenocarcinoma in one of the following risk groups as defined by NCCN criteria:
- •Unfavorable intermediate risk. Intermediate risk is defined as having no high-risk or very high-risk factors and having at least one of the following intermediate risk factors (IRFs):
- •cT2b-cT2c
- •Grade Group 2 or 3
- •PSA 10-20 ng/mL
- •Unfavorable intermediate risk additionally must have one or more of the following:
- •2 or 3 IRFs
- •Grade Group 3
- •≥50% biopsy cores positive (eg, ≥ 6 of 12 cores) OR
Exclusion Criteria
- •Current or previous treatment with SGLT2i or thiazolidinedione.
- •Currently receiving regularly scheduled systemic steroids in the form of prednisone or dexamethasone (more than 10 mg prednisone daily or equivalent). Topical steroid ointments or creams for occasional skin rash is allowed.
- •A history of other malignancy with the exceptions of malignancies for which all treatment was completed at least 2 years before registration with no evidence of disease and locally treated skin squamous or basal cell carcinoma.
- •History of stroke or transient ischemic attack in the last 5 years.
- •Patients with type 1 diabetes mellitus will be excluded or patients with insulin-requiring diabetes mellitus will be excluded. Only patients with well-controlled type 2 diabetes mellitus will be allowed.
- •Screening HbA1c \> 10%, unless approved by endocrinologist.
- •Currently receiving any other investigational agents.
- •A history of allergic reactions attributed to compounds of similar chemical or biologic composition to dapagliflozin.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, peripheral arterial disease, ketoacidosis, severe kidney disease (estimated glomerular filtration rate eGFR \< 30 mL/min/1.73m2), symptomatic hypotension, and chronic/frequent urinary tract infections or yeast infections.
- •Patients with HIV are eligible unless their CD4+ T-cell counts are \< 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
Arms & Interventions
Dapagliflozin
* Dapagliflozin will be initiated once daily approximately 6 weeks prior to planned prostatectomy * Dapagliflozin will be given at 10 mg by mouth once daily for 4 weeks (days 1-28) prior to prostatectomy.
Intervention: Dapagliflozin
Outcomes
Primary Outcomes
Proportion of patients who are able to successfully complete at least 80% of the planned dapagliflozin doses and undergo radical prostatectomy
Time Frame: At approximately 6 weeks
The study will be feasible if at least 19 of the 24 enrolled subjects are able to complete at least 80% of the planned dapagliflozin doses and undergo radical prostatectomy as scheduled.
Frequency and severity of toxicities related to dapagliflozin as measured by CTCAE v 5.0
Time Frame: From cycle 1 day 1 (the cycle is 28 days in length) through 30 days after prostatectomy (approximately day 64)
Secondary Outcomes
- Degree of tumor necrosis/shrinking(From screening to time of radical prostatectomy (estimated to be at week 6))
- Change in plasma glucose(From screening to day 29)
- MRI quantified change in tumor size from screening to post-treatment(At the time of pre-operative prostate MRI (estimated to be at week 6))
- Change in C-peptide(From screening to day 29)
- Change in HbA1C(From screening to day 29)
- Change in glucagon(From screening to day 29)